Earnings summaries and quarterly performance for Charlotte's Web Holdings.
Executive leadership at Charlotte's Web Holdings.
Board of directors at Charlotte's Web Holdings.
Research analysts who have asked questions during Charlotte's Web Holdings earnings calls.
Recent press releases and 8-K filings for CWBHF.
Charlotte's Web Reports Q3 2025 Results with Strategic Shifts
CWBHF
Earnings
Product Launch
Board Change
- Charlotte's Web Holdings, Inc. reported Q3 2025 revenue of $11.5 million, a decrease from $12.6 million in Q3 2024, primarily reflecting a strategic B2B business model transformation. The company posted a net loss of $(5.9) million in Q3 2025, comparable to $(5.8) million in Q3 2024.
- Adjusted EBITDA improved to $(2.1) million in Q3 2025 from $(3.9) million in Q3 2024, largely due to a 23.3% reduction in SG&A expenses to $9.7 million.
- The company anticipates approximately $9 million in total annualized cost savings in 2026 from ongoing expense reductions and manufacturing efficiencies, including $3 million from the internalization of Brightside™ gummy production.
- Gross profit for Q3 2025 was $4.5 million, or 38.9% of revenue, impacted by a $0.5 million B2B retail chargeback reserve and temporary scaling inefficiencies, though gross margin is expected to rebound in Q4 2025 as in-house production scales.
- Charlotte's Web expanded its product portfolio with new Brightside™ hemp-derived delta-9 products and an expanded sleep category, and appointed M. Borgia Walker to its Board of Directors effective November 1, 2025.
Nov 12, 2025, 12:07 PM
Charlotte's Web Reports Q3 2025 Results
CWBHF
Earnings
Product Launch
New Projects/Investments
- Charlotte's Web Holdings, Inc. reported Q3 2025 revenue of $11.5 million, an 8.6% decrease from Q3 2024, with a net loss of $(5.8) million and Adjusted EBITDA of $(2.1) million, an improvement from $(3.9) million in Q3 2024.
- The company implemented a strategic restructuring of its B2B retail operations and completed internalization of Brightside™ gummy production, leading to a 23.3% reduction in SG&A expenses to $9.7 million in Q3 2025 and an expected $9 million in annualized cost savings in 2026.
- Product innovation continued with the launch of Brightside™ hemp-derived delta-9 products and an expanded sleep portfolio, including CBN Stay Sleep Gummies becoming the second-best-selling gummy product.
- DeFloria, Inc., a collaboration, received clearance for FDA Phase 2 clinical trials for an investigational botanical drug to treat irritability associated with autism spectrum disorder (ASD), with Charlotte's Web retaining exclusive manufacturing rights for commercial supply.
- M. Borgia Walker was appointed to the Board of Directors, effective November 1, 2025.
Nov 12, 2025, 12:07 PM
Quarterly earnings call transcripts for Charlotte's Web Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more